Mobile

A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety ofranibizumab 0.3 mg and 0.5 mg administered as twodosing regimens in patients with subfoveal chor...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003517-33

A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety ofranibizumab 0.3 mg and 0.5 mg administered as twodosing regimens in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Critère d'inclusion

  • Wet age-related macular degeneration of retina

Liens